Sauer Paul
Known title: SVP Process Dev, ManufacturingCIK: 0001813796
Associated companies
Transaction History
| PCVX | ▼ Sell | Tax Withholding | 865 | $23K | 9/2/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 3,000 | $78K | 8/22/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 3,000 | $75K | 7/27/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 3,000 | $75K | 7/20/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 3,000 | $79K | 5/23/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 3,000 | $75K | 4/22/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 3,000 | $75K | 3/22/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 6,000 | $150K | 3/10/2022 | View on chart |
| PCVX | ▲ Buy | Grant | 10,000 | $0 | 3/2/2022 | View on chart |
| PCVX | ▼ Sell | Open Market | 6,000 | $150K | 12/29/2021 | View on chart |
| PCVX | ▼ Sell | Open Market | 3,000 | $75K | 11/1/2021 | View on chart |
| PCVX | ▼ Sell | Open Market | 5,307 | $134K | 9/22/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints
Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.
Vaxcyte VAX-31 clears Phase III OPUS-1 trial endpoints. Vaxcyte announced that its VAX-31 vaccine met all primary endpoints in the pivotal Phase III OPUS-1 trial. This positive data point positions the company for additional readouts expected in the first half of 2027. The stock is currently trading near its 52-week high, reflecting strong market interest in the clinical progress.